TICKERNERD
Menu
APVOAPVOHealthcare · Biotechnology

APVO Stock Forecast: Aptevo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$1.61
+0.63% on the day

The 1 Wall Street analysts covering Aptevo Therapeutics, Inc. hold a median 12-month price target of $26 — +1483.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.9M
Ticker Nerd rank
30/ 100
Median analyst target
$26
Analysts covering
1
Revenue$0.0
Operating income−$6.4M
Net income−$6.4M
Free cash flow−$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.3%
1M
−13.0%
YTD
−82.9%
1Y
−94.1%
From 52W high
−94.3%
From 52W low
+0.6%
$2
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aptevo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
30/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Accruals
80
Revisions
72
Volatility
59
Growth
25
Issuance
23
Quality
17
Value
7
Momentum
3

Size (97): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Jan 26Apr 26Jul 26Oct 26APVOHigh $30Median $26Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $21Median $26High $30

The green dot is the last close — the median target sits +1483.9% from it.

Recent analyst actionsNewest first

Of the 9 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
23 Sept 2024Roth MKMMaintainsBuy$15 → $8.00
13 May 2022Piper SandlerMaintainsOverweight$69 → $20
28 May 2021Roth CapitalMaintainsBuy$64 → $50
25 Nov 2020PiperJaffrayInitiatesOverweight—
25 Nov 2020Roth CapitalInitiatesBuy—
11 Nov 2020Piper SandlerMaintainsOverweight$32 → $69
11 Apr 2018Roth CapitalInitiatesBuy—
9 Sept 2016Piper SandlerInitiatesOverweight—
9 Sept 2016PiperJaffrayInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

APVO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

APVO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Aptevo Therapeutics, Inc. returned −94.1% against +15.6% for the S&P 500, dividends included.

APVO vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26APVOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aptevo Therapeutics, Inc. (APVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−420.3%

Higher than 4% of US stocks

Return on assets
−111.5%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aptevo Therapeutics, Inc. (APVO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aptevo Therapeutics, Inc. has a market value of $2.9M and an enterprise value of −$2.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$26.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$25.3M.

  • Shares outstanding: 1.2M.

  • Trailing P/E: 0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aptevo Therapeutics, Inc. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

APVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APVOAptevo Therapeutics, Inc.$2.9M30
PPCBPropanc Biopharma, Inc.$2.8M52
MBIOMustang Bio, Inc.$2.8M14
CMNDClearmind Medicine, Inc.$3.0M6
SXTP60 Degrees Pharmaceuticals, Inc.$3.1M41
GRIGRI Bio, Inc.$3.1M34
VIVSVivoSim Labs, Inc.$2.6M38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aptevo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APVO news & analysis

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Accesswire · 14 Oct 2026positive

Aptevo announced it will present its multispecific platform at the SITC 2026 Annual Meeting, scheduled for November 4–8 in Phoenix. The presentation will feature its CD40-directed multispecific portfolio and its approach to coordinating innate and adaptive immunity within the tumor microenvironment.

Why it matters — The presentation will showcase Aptevo’s multispecific platform and broader CD40-directed portfolio to the cancer immunotherapy community.

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Accesswire · 24 Sept 2026positive

Aptevo Therapeutics announced progress in its next-generation trispecific programs, stating it is optimizing several trispecific candidates for reliable, scalable manufacturing as an essential step toward future human testing. The company described these trispecifics as combining three complementary cancer-fighting functions in one molecule.

Why it matters — APVO watchers would care because this progress moves the company's pipeline toward clinical development and human testing.

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Benzinga · 3 Sept 2026positive

Aptevo Therapeutics announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when used as a triplet therapy in frontline acute myeloid leukemia patients with TP53 mutations.

Why it matters — This result reflects strong preliminary efficacy for Aptevo's lead pipeline candidate in a difficult-to-treat leukemia patient population.

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Accesswire · 3 Sept 2026positive

Aptevo Therapeutics announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia patients with TP53 mutations, a difficult-to-treat subpopulation historically responding poorly to treatment. The company noted that remission results nearly double published venetoclax/azacitidine outcomes. The announcement was made on September 3, 2026.

Why it matters — Aptevo watchers would care because these early clinical results suggest the mipletamig triplet may address a notoriously hard-to-treat AML patient population, potentially differentiating the company's lead candidate in a challenging disease setting.

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Accesswire · 14 Aug 2026positive

Aptevo Therapeutics reported its second-quarter 2026 financial results and provided a business update. The update highlighted strong clinical progress for mipletamig, including data in frontline acute myeloid leukemia and a path toward Phase 2, the appointment of a Chief Scientific Officer, non-dilutive grant funding advancing its trispecific pipeline, and a 50/50 collaboration with Niowave to pursue radiopharmaceutical therapeutic development.

Why it matters — APVO watchers would note the combination of advancing clinical data, strengthened leadership, non-dilutive funding, and a new partnership as signals of pipeline progress across multiple therapeutic areas.

FAQ

Frequently asked questions about APVO stock

What is the APVO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Aptevo Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $21 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APVO stock a buy right now?

Of the 1 analysts covering Aptevo Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aptevo Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APVO?

As at 22 Oct 2026, Aptevo Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will APVO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1483.9% from the last close, and Ticker Nerd's factor model ranks Aptevo Therapeutics, Inc. 30 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APVO stock forecast for 2030?

No analyst covering Aptevo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $30 over the next 12 months.

How has APVO stock performed over the past year?

Aptevo Therapeutics, Inc. returned -94.1% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aptevo Therapeutics, Inc. do?

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer.

What is the latest news on APVO?

The most recent item we track (Accesswire, 14 Oct 2026): "Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting". Aptevo announced it will present its multispecific platform at the SITC 2026 Annual Meeting, scheduled for November 4–8 in Phoenix. The presentation will feature its CD40-directed multispecific portfolio and its approach to coordinating innate and adaptive immunity within the tumor microenvironment.

Company

About Aptevo Therapeutics, Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer. The company uses its proprietary ADAPTIR and ADAPTIR-FLEX platforms to design mono-, bi-, and multi-specific antibody-based therapeutics intended to engage the immune system against tumor cells. Its current pipeline includes candidates for hematologic malignancies and solid tumors, with programs spanning clinical and preclinical development. Aptevo Therapeutics Inc. operates in the oncology and immuno-oncology segments of the healthcare market, where it contributes to the development of targeted biologic therapies for complex cancers. Headquartered in Seattle, Washington, the company concentrates on research-driven product development and collaboration-based innovation in modern cancer treatment.

CEO Mr. Jeffrey G. Lamothe CA · 33 employees · United States · https://aptevotherapeutics.com